BCI.INTEL
NLINKN1 Chip+PRIME.StudySYNCRStentrode+$75M.SeriesDPRECNLayer 7+FDA.BrkthruPARAMArgo+$20M.SeriesBBLKRKNeuroport+200.ImplantsEMTIVMN8+$45M.SeriesBKRNLFlux+Non-invasiveNRBLEHalo+Consumer.BCINEURONeuroPace+RNS.SystemCOGNICognixion+ALS.TrialFUND.YTD2026$2.8B.SectorTRIALSActive50+.ClinTrialsIMPLNTSHumans~100.Intracrtnl

Patient Implant Data

Aggregated implant statistics for every BCI company with human trial participants. Data sourced from published trial results, company disclosures, and ClinicalTrials.gov.

Total Implanted (All Time)
204,102
Currently Active
178,826
Companies with Human Trials
7
Data Sources
ClinicalTrials.gov
NeuralinkN1 Implant
ALS, quadriplegia, spinal cord injury
Implanted
3
Active
3
Phase
PRIME Feasibility Study
SynchronStentrode
ALS, motor neuron disease, locked-in syndrome
Implanted
10
Active
9
Phase
SWITCH / COMMAND
Precision NeuroscienceLayer 7 Cortical Interface
Intraoperative cortical mapping (elective neurosurgery patients)
Implanted
50
Active
0
Phase
PATTERN I (acute intraoperative only)
BrainGate ConsortiumUtah Array (96-electrode)
ALS, spinal cord injury, locked-in syndrome, brainstem stroke
Implanted
33
Active
8
Phase
BrainGate2 (Phase I)
NeuroPaceRNS System
Drug-resistant focal epilepsy
Implanted
4000
Active
3800
Phase
Commercial (post-PMA 2013)
NCT ID
—
Second Sight / VivaniOrion Visual Cortical Prosthesis
Profound bilateral blindness
Implanted
6
Active
6
Phase
Phase I/II (suspended)
Medtronic NeuromodulationPercept PC / DBS systems
Parkinson's disease, essential tremor, epilepsy, OCD, dystonia
Implanted
200000
Active
175000
Phase
Commercial (DBS since 1997; Percept PC since 2020)
NCT ID
—

This page is for informational purposes only and does not constitute medical advice. Always consult a qualified physician before making any medical decisions.